Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study

Summary Background Vedolizumab (VDZ) is a humanised monoclonal IgG1 antibody targeting α 4 β 7 integrin. Aim To investigate the real‐world efficacy of vedolizumab for the treatment of Crohn's disease ( CD ) and ulcerative colitis ( UC ). Methods A consecutive cohort of 212 adult IBD patients with active disease ( HBI >7/partial Mayo >4) newly receiving VDZ was prospectively recruited from 7 academic and 17 community centres. The primary...